A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Study summary

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986489 (Atigotatug+Nivolumab) and Atezolizumab

Plus 2 other study approaches.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 11, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 3

Interventional

Where is it offered?183 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: Bristol-Myers Squibb
Interventions being studied: Biological: BMS-986489 (Atigotatug+Nivolumab); Biological: Atezolizumab; Drug: Carboplatin; Drug: Etoposide

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Small cell lung cancer (SCLC)→

Treatment approach

Immunotherapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

Reasons someone may not be able to joinExclusion criteria

Participants have already received certain types of treatment for extensive stage small cell lung cancer
Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
Other protocol-defined Inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Southern Cancer Center, PCDaphne, Alabama
Local Institution - 0283Hot Springs, Arkansas
Florida Cancer Specialists - SouthFort Myers, Florida
Mid Florida Hematology and Oncology CenterOrange City, Florida
Florida Cancer Specialists - NorthSt. Petersburg, Florida
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb HospitalMarietta, Georgia
Illinois Cancer CarePeoria, Illinois
Local Institution - 0037Minneapolis, Minnesota
University of New Mexico Comprehensive Cancer CenterAlbuquerque, New Mexico
Duke Cancer InstituteDurham, North Carolina
Sanford Medical CenterBismarck, North Dakota
Sanford Fargo Medical CenterFargo, North Dakota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 11, 2026. Always confirm current availability with the study team.

View original record ↗